Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma

Rev Col Bras Cir. 2009 Feb;36(1):24-34. doi: 10.1590/s0100-69912009000100007.


Objectives: To correlate the expression of p53 protein and VEGF with the prognosis of patients submitted to curative resection to treat esophageal adenocarcinoma.

Methods: Forty-six patients with esophageal adenocarcinoma, submitted to curative resection, were studied. The expressions of p53 protein and VEGF were assessed by immunohistochemistry in 52.2% and 47.8% of tumors, respectively.

Results: P53 protein and VEGF expressions coincided in 26% of the cases, and no correlation between these expressions was observed. None of the clinicopathological factors showed a significant correlation with p53 protein or VEGF expressions. There was no significant association between p53 protein and VEGF expressions and long-term survival.

Conclusion: The expression of p53 protein and VEGF did not correlate with prognosis in esophageal adenocarcinoma patients submitted to curative resection.

MeSH terms

  • Adenocarcinoma / chemistry
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / mortality*
  • Adult
  • Aged
  • Esophageal Neoplasms / chemistry
  • Esophageal Neoplasms / metabolism*
  • Esophageal Neoplasms / mortality*
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Survival Rate
  • Time Factors
  • Tumor Suppressor Protein p53 / analysis
  • Tumor Suppressor Protein p53 / biosynthesis*
  • Vascular Endothelial Growth Factor A / analysis*
  • Vascular Endothelial Growth Factor A / biosynthesis*


  • Tumor Suppressor Protein p53
  • Vascular Endothelial Growth Factor A